A Prospective, Double-blind, Randomized, Parallel, Multiple-center Study to Compare the Efficacy and Safety of 1PC002 and Atorvastatin in Taiwanese Patients With Hypercholesterolemia
Latest Information Update: 19 Jul 2023
Price :
$35 *
At a glance
- Drugs Pitavastatin (Primary) ; Atorvastatin
- Indications Hypercholesterolaemia
- Focus Biomarker; Registrational; Therapeutic Use
- Sponsors Orient Pharma
- 14 Jun 2013 Actual initiation date changed from Sep 2011 to Nov 2011 as reported by ClinicalTrials.gov.
- 12 Nov 2012 New trial record